Tetracyclic antidepressant

Tetracyclic antidepressants (TeCAs) are a class of antidepressants that were first introduced in the 1970s. They are named after their chemical structure, which contains four rings of atoms, and are closely related to the tricyclic antidepressants (TCAs), which contain three rings of atoms.

History

The first TeCA, maprotiline, was introduced in the 1970s. It was followed by mianserin in 1977 and amoxapine in 1992. These medications were developed as a result of research aimed at finding new and more effective treatments for depression.

Mechanism of action

TeCAs work by inhibiting the reuptake of certain neurotransmitters in the brain, including norepinephrine, serotonin, and, to a lesser extent, dopamine. This increases the levels of these neurotransmitters in the brain, which can help to alleviate the symptoms of depression.

Uses

TeCAs are primarily used to treat major depressive disorder, but they can also be used to treat other conditions, such as anxiety disorders, obsessive-compulsive disorder (OCD), and certain types of chronic pain.

Side effects

Like all medications, TeCAs can cause side effects. These can include drowsiness, dizziness, dry mouth, constipation, blurred vision, and weight gain. In rare cases, they can also cause more serious side effects, such as suicidal thoughts or behaviors.

See also

• Antidepressant
• Tricyclic antidepressant
• Selective serotonin reuptake inhibitor
• Serotonin-norepinephrine reuptake inhibitor

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia